Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11240618 | 0.90 | MGAM (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL1194353 | 0.84 | GAA (0.50) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL28036047 | 0.80 | GAA (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL460011 | 0.80 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL27845082 | 0.80 | MGAM (0.55) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL27828 | 0.80 | — | — | |
| SCHEMBL14485615 | 0.79 | MGAM (0.41) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL1195198 | 0.79 | CYP1A2 (0.39) | MGAMGAASIMGAM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29184752 | 0.78 | MGAM (0.52) | MGAMGAASIMGAM2ALDH1A1 | |
| Ethane SCHEMBL15442720 | 0.78 | MGAM (0.52) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411431-A1 | Novel compounds and their use in therapy | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| US-11466011-B2 | Compounds and their use as inhibitors of N-myristoyl transferase | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-10-11 | — | — | US | disclosed |
| EP-3313833-B1 | COMPOUNDS AND THEIR USE AS INHIBITORS OF N-MYRISTOYL TRANSFERASE | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2021-01-06 | — | — | EP | disclosed |
| US-20200339586-A1 | Compounds And Their Use As Inhibitors Of N-Myristoyl Transferase | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-10-29 | — | — | US | disclosed |
| US-10759804-B2 | Compounds and their use as inhibitors of N-myristoyl transferase | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| US-20180370974-A1 | Compounds And Their Use As Inhibitors Of N-Myristoyl Transferase | IMPERIAL INNOVATIONS LIMITED (GB) | 2018-12-27 | — | — | US | disclosed |
| EP-3313833-A1 | COMPOUNDS AND THEIR USE AS INHIBITORS OF N-MYRISTOYL TRANSFERASE | Imperial Innovations Ltd (GB) | 2018-05-02 | — | — | EP | disclosed |
| WO-2017001812-A1 | COMPOUNDS AND THEIR USE AS INHIBITORS OF N-MYRISTOYL TRANSFERASE | IMPERIAL INNOVATIONS LIMITED (GB) | 2017-01-05 | — | — | WO | disclosed |
| EP-2155717-B1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-10-24 | — | — | EP | disclosed |
| US-8202873-B2 | 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines as 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-06-19 | — | — | US | disclosed |
| EP-2040700-B1 | N- (PHENYLMETHYL) -2- (1H-PYRAZ0L-4-YL) ACETAMIDE DERIVATIVES AS P2X7 ANTAGONISTS FOR THE TREATMENT OF PAIN, INFLAMMATION AND NEURODEGENERATION | GLAXO GROUP LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| US-20100120785-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2155717-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009074519-A1 | COMBINATIONS OF PYRAZOLYL OR ISOXAZOLYL P2X7 MODULATORS WITH FURTHER THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149524-A1 | N-(Phenylmethyl)-2-(1H-Pyrazol-4-yl) Acetamide Derivatives as P2X7 Antagonists for the Treatment of Pain, Inflammation and Neurodegeneration | GLAXO GROUP LIMITED (GB) | 2009-06-11 | — | — | US | disclosed |
| EP-2040700-A1 | N- (PHENYLMETHYL) -2- (1H-PYRAZ0L-4-YL) ACETAMIDE DERIVATIVES AS P2X7 ANTAGONISTS FOR THE TREATMENT OF PAIN, INFLAMMATION AND NEURODEGENERATION | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008141020-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2007141267-A1 | N- (PHENYLMETHYL) -2- (1H-PYRAZ0L-4-YL) ACETAMIDE DERIVATIVES AS P2X7 ANTAGONISTS FOR THE TREATMENT OF PAIN, INFLAMMATION AND NEURODEGENERATION | GLAXO GROUP LIMITED (GB) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759804-B2 | Compounds and their use as inhibitors of N-myristoyl transferase | NMT1, NMT2, GNMT | MGAM 402/4885GAA 580/4885SI 992/4885 |
| US-20090149524-A1 | N-(Phenylmethyl)-2-(1H-Pyrazol-4-yl) Acetamide Derivatives as P2X7 Antagonists for the Treatment of Pain, Inflammation and Neurodegeneration | P2RX3, P2RX7, P2RX1 | MGAM 4030/4885GAA 2136/4885SI 3758/4885 |
| US-20220411431-A1 | Novel compounds and their use in therapy | NMT1, NMT2, FNTA | MGAM 810/4885GAA 526/4885SI 1721/4885 |
| US-11466011-B2 | Compounds and their use as inhibitors of N-myristoyl transferase | NMT1, NMT2, GNMT | MGAM 402/4885GAA 580/4885SI 992/4885 |
| US-20180370974-A1 | Compounds And Their Use As Inhibitors Of N-Myristoyl Transferase | NMT1, NMT2, GNMT | MGAM 402/4885GAA 580/4885SI 992/4885 |
| US-20100120785-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | HTR7, HTR2C, HTR4 | MGAM 4874/4885GAA 4789/4885SI 4743/4885 |
| US-20200339586-A1 | Compounds And Their Use As Inhibitors Of N-Myristoyl Transferase | NMT1, NMT2, GNMT | MGAM 402/4885GAA 580/4885SI 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.